Oramed Pharmaceuticals Inc. (ORMP) stock
ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30
$3.87−0.03 (-0.77%)
Close on Nov 17, 2026Market cap $160.98MP/E 0.9Yield 6.46%
Oramed Pharmaceuticals pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Oramed Pharmaceuticals's pe ratio was 1.0× on Nov 11, 2026, against 2.9× a year earlier. Over the last 4 years it ranged from 1.0× to 43.2×, with a median of 9.2×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 1.0× | −1.9 |
| 2025 | Dec 31, 2025 | 2.9× | −24.0 |
| 2024 | Dec 31, 2024 | 26.9× | +23.2 |
| 2020 | Mar 31, 2020 | 3.7× | −2.6 |
| 2019 | Dec 31, 2019 | 6.3× | −2.9 |
| 2015 | Jun 30, 2015 | 9.2× | +1.8 |
| 2014 | Dec 31, 2014 | 7.4× | −21.6 |
| 2013 | Dec 31, 2013 | 28.9× | – |
See a number that looks wrong?